ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0733

Global Identification of Lupus Genetic Risk Variants Facilitating the Type I Interferon Pathway Through CRISPR-based Genomic Screening

Guojun Hou1, Xinyi Zhu1, Yutong Zhang1, Zhaorui Cheng1 and Nan Shen2, 1Shanghai Institute of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University (SJTUSM), Shanghai, China, 2Shanghai Jiao Tong University School of Medicine, Shanghai, China

Meeting: ACR Convergence 2023

Keywords: Gene Expression, genetics, genomics, interferon, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: Abstracts: Genetics, Genomics & Proteomics

Session Type: Abstract Session

Session Time: 2:00PM-3:30PM

Background/Purpose: Genome-Wide Association Studies (GWAS) have unveiled over 1000 risk variants for lupus, predominantly situated in non-coding genomic regions. Their functional roles, especially their potential impacts on the dysregulated type I interferon pathway inherent in lupus, remain largely uncharted. To bridge this knowledge gap, our study employs CRISPR/Cas9 technology, enabling a deeper exploration into the functional implications of these risk loci.

Methods: Our novel strategy entailed CRISPR-based screening for functional variants that regulate the type I interferon pathway. We collected all known SLE-associated SNPs and expanded them through linkage disequilibrium in the population where the SNP was reported. We designed an sgRNA library covering these SLE-associated SNPs and developed a cellular model using U-937, Jurkat, and Raji cells that stably express the CRISPR/Cas9-ISRE-GFP and CRISPR/SAM-ISRE-GFP systems. Post-transduction with the sgRNA lentiviral library, we sorted cells based on GFP intensity and extracted and sequenced DNA from these sorted cells. The functional variants were identified and characterized using multi-omics analysis (eQTL data, HiC data, RNA-sequencing data). We validated the function of the rs11152966-located region and identified PRDM1 as the target gene of rs11152966 through integration of advanced technologies like capture-HiC, CRISPR-SAM, and prime editing technology.

Results: We’ve characterized the comprehensive landscape of functional SNPs related to lupus that regulate the Type I interferon pathway. Notably, we discovered that the majority of these functional variant regions are cell type-specific .Utilizing the CRISPR/Cas9 and CRISPR/SAM systems effectively, we found these tools to have complementary benefits in the identification of these functional variants. Furthermore, these functional variant regions were found to be associated with the expression of critical regulators within the JAK-STAT pathway and interferon-stimulated genes (ISGs). Importantly, we observed a correlation between the expression of transcription factors disrupted by these functional variants and the expression of ISGs in SLE patients. One standout finding was the negative regulatory effect on the Type I interferon pathway upon activation of the region containing the SNP rs11152966. This region, inclusive of the SNP, forms a gene loop with the PRDM1 promoter, thereby managing PRDM1 expression. Additionally, we provided evidence that PRDM1 acts as a novel negative regulator of the Type I interferon pathway. Lastly, our research revealed a link between the presence of the risk allele T and a reduction in PRDM1 expression. This reduced expression appears to be due to the allele T’s effect on the binding of the transcription factor SPI1.

Conclusion: Our study leveraged advanced gene-editing tools to elucidate the landscape of functional SNPs in lupus, revealing their cell type-specific regulation of the Type I interferon pathway and their influence on key genes in the JAK-STAT pathway. Notably, we highlighted the significant role of SNP rs11152966 and its target gene PRDM1 in regulating the interferon pathway in lupus.

Supporting image 1

Figure 1. Functional Variant Screening for Regulation of Type I Interferon Pathway Activation Using CRISPR/SAM and CRISPR/Cas9 Across Various Immune Cells. (A) A depiction of the CRISPR screening workflow. (B) Representation of the proportion of functional regions implicated in the modulation of the type I interferon pathway. (C) Evaluation of functional variant regions that are common or specific to individual cell types.

Supporting image 2

Figure 2. Annotation of SNP-Target Gene-TF Interaction Network and Their Role in the Interferon (IFN) Pathway (A-B) Illustrates the interconnection of functional SNPs and associated genes in the JAK-STAT signaling pathway and ISGs, with lines denoting eQTL signals or 3D genomic interactions. Gene size and color correspond to differential expression results in SLE patients. (C) Shows a network of functional SNPs, disrupted TFs due to SNP, and ISGs with significant correlation to these TFs. Gray lines suggest disruption of TF binding motifs by SNPs. Blue and red lines indicate negative and positive correlations between ISGs and TFs, respectively. TF size and color display its degree or interaction count, as determined by Cytoscape. (D) Demonstrates Spearman correlation analysis between transcription factors and ISGs expression levels (RPKMs) in whole blood samples from SLE patients.

Supporting image 3

Figure 3. PRDM1 expression is regulated by rs11152966, contributing to the modulation of the type Ⅰ interferon pathway. (A) A region containing rs11152966, revealed by CRISPR screening, inhibits the activation of the type Ⅰ interferon pathway. (B) Gene loop between the rs11152966 location and PRDM1 promoter, as evidenced by HiC data. (C-E) CRISPR/SAM targeting the area containing rs11152966 boosts PRDM1 expression, but not the adjacent gene ATG5. (F-G) Targeting of the PRDM1 TSS region by CRISPR/SAM results in reduced ISGs expression. (H-I) Analysis by GSEA of JAK-STAT and SLE pathways in PRDM1 KO U-937 cells post-IFNα stimulation for 1 hour. (J) Genotype of rs11152966 in cell clones established by prime editing technology. (K) The T risk allele of rs11152966 results in diminished PRDM1 expression compared to the C non-risk allele. (L) SPI1 has a preference for binding to the non-risk C allele of rs11152966. (M) ChIP-seq data indicate SPI1 binding within the rs11152966 region. (N-O) PRDM1 expression following SPI1 overexpression or knockdown.


Disclosures: G. Hou: None; X. Zhu: None; Y. Zhang: None; Z. Cheng: None; N. Shen: None.

To cite this abstract in AMA style:

Hou G, Zhu X, Zhang Y, Cheng Z, Shen N. Global Identification of Lupus Genetic Risk Variants Facilitating the Type I Interferon Pathway Through CRISPR-based Genomic Screening [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/global-identification-of-lupus-genetic-risk-variants-facilitating-the-type-i-interferon-pathway-through-crispr-based-genomic-screening/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/global-identification-of-lupus-genetic-risk-variants-facilitating-the-type-i-interferon-pathway-through-crispr-based-genomic-screening/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology